Is metformin cardioprotective?

Diabetes Care

Volumn 26, Issue 1, 2003, Pages 243-244

  Sasali, Afshin ^b   Leahy, Jack L ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; ORAL ANTIDIABETIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; SULFONYLUREA DERIVATIVE;

CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DIABETES MELLITUS; EDITORIAL; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; SCORING SYSTEM;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; RISK FACTORS;

EID: 0037552336     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.1.243     Document Type: Editorial

References (19)

1. Johnson JA, Majumdar SR, Simpson SH, Toth EL: Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25:2244-2248, 2002
2. U.K. Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UK-PDS 34). Lancet 352:854-865, 1998
3. U.K. Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
4. Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
5. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287:360-372, 2002
6. Turner RC, Holman RR: Metformin and risk of cardiovascular disease. Cardiology 91:203-204, 1999
7. Harris MI, Hamman RF (Eds.): Diabetes in America. 2nd ed. Washington, DC, U.S. Govt. Printing Office, 1995 (DHHS publ. no. 85-1468)
8. DeFronzo RA, Goodman AM: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 31:333:541-549, 1995
9. Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, D'Onofrio F: Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 16:1387-1390, 1993
10. Charles MA, Morange P, Eschwege E, Andre P, Vague P, Juhan-Vague I: Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study: Biguanides and the Prevention of the Risk of Obesity. Diabetes Care 21:1967-1972, 1998
11. Nathan DM: Some answers, more controversy, from UKPDS. Lancet 352:832-833, 1998
12. Fisman EZ, Tenenbaum A, Benderly M, Goldbourt U, Behar S, Motro M: Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Cardiology 91:195-202, 1999
13. Fisman EZ, Tenenbaum A, Boyko V, Benderly M, Adler Y, Friedensohn A, Kohanovski M, Rotzak R, Schneider H, Behar S, Motro M: Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 24:151-158, 2001
14. University Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 25:1129-1153, 1976
15. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM: Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 103:3111-3116, 2001
16. Scognamiglio R, Avogaro A, Vigili de Kreutzenberg S, Negut C, Palisi M, Bagolin E, Tiengo A: Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 51:808-812, 2002
17. Ginsberg H, Plutzky J, Sobel BE: A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. J Cardiovasc Risk 6:337-346, 1999
18. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA: Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 134:61-71, 2001
19. Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B: Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22:717-726, 2002